Connect Biopharma announces board resignation amid U.S. transition

Connect Biopharma Holdings ( (CNTB) ) has provided an update.

On December 17, 2025, Connect Biopharma Holdings announced that Kan Chen, Ph.D., a partner at Qiming Venture Partners, resigned from its board of directors and from the nominating and corporate governance committee, effective immediately. The company said Chen’s departure was not due to any disagreement over operations, policies or practices, and noted that he viewed the timing as appropriate following the company’s successful strategic transition to a U.S.-based management team and drug development activities primarily in the U.S. and Europe, which he believes has positioned the company for future growth.

The most recent analyst rating on (CNTB) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Connect Biopharma Holdings stock, see the CNTB Stock Forecast page.

Spark’s Take on CNTB Stock

According to Spark, TipRanks’ AI Analyst, CNTB is a Neutral.

Connect Biopharma Holdings’ overall score reflects the challenges of unprofitability and negative cash flow despite recent revenue growth and a strong balance sheet. Technical indicators suggest a bearish trend, while the valuation highlights the risks typical of early-stage biotech firms. However, the positive corporate event regarding FDA support for Phase 2 trials offers a promising growth opportunity in the pipeline, improving the outlook.

To see Spark’s full report on CNTB stock, click here.

More about Connect Biopharma Holdings

Connect Biopharma Holdings Limited is a biopharmaceutical company focused on drug development, with recent operations and management increasingly centered in the United States and Europe rather than China, reflecting a strategic shift toward a more U.S.-centric business model.

Average Trading Volume: 276,609

Technical Sentiment Signal: Buy

Current Market Cap: $126.9M

Find detailed analytics on CNTB stock on TipRanks’ Stock Analysis page.